Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:

Multiple Sclerosis Clinical Trial

Official title:

Effect of Photobiomodulation Treatment in the Sublingual Region and Along the Spinal Column in Individuals With Multiple Sclerosis: Protocol for a Randomized, Controlled, Double-blind, Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03360487
• Other study ID #: FBMEM
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2018
• Est. completion date: February 28, 2019

Study information

• Verified date: October 2018
• Source: University of Nove de Julho
• Contact: Tamiris da Silva, MS
• Phone: 1125571502
• Email: tamiris.slv[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Multiple sclerosis (MS) is an autoimmune disease, for which the forms of treatment are medication and rehabilitation. However, in vitro and in vivo studies have demonstrated that photobiomodulation can be an effective treatment modality for inflammatory diseases, including MS. Photobiomodulation has a broad range of benefits, such as the avoidance of cell and tissue death, the stimulation of healing and injury repair, reductions in pain, edema and inflammation, cell proliferation and even apoptosis. The outcomes of photobiomodulation include the regeneration of cells, the stimulation of the growth of Schwann cells, a reduction in spasticity, functional improvements, a reduction in nitric oxide levels and the upregulation of the cytokine IL10, demonstrating that this therapeutic modality can offer neuro-protection.

Methods: A randomized, controlled, double-blind, clinical trial is proposed. The patients will be divided into six groups. Groups 1 and 2 will receive sham and active photobiomodulation in the sublingual region, respectively. Groups 3 and 4 will receive sham and active photobiomodulation along the spinal cord, respectively. Group 5 will receive placebo treatment with photobiomodulation on the skin in the region of the radial artery with a specific bracelet. Group 6 will be treated with photobiomodulation on the skin in the region of the radial artery with a specific bracelet.

Discussion: Treatment for MS is directed at the immune response and slowing the progression of the disease. This is one of the first clinical trials with sublingual and along the spinal cord photobiomodulation, which could help establish a new, promising treatment of the disease associated with pharmacological treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: February 28, 2019
• Est. primary completion date: December 31, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Diagnosis of MS;

• Age between 18 and 60 years;

• Currently undergoing pharmacological treatment;

• Capable of understanding and following verbal instructions;

• score of < 7 on the Expanded Disability Status Scale;

• No restriction will be imposed regarding gender.

Exclusion Criteria:

• Other autoimmune diseases;

• Neoplasias;

• Heart failure;

• Respiratory failure;

• Renal insufficiency;

• Hepatic insufficiency;

• Acquired immunodeficiency syndrome;

• Patients with relapses of the disease will be excluded from the study.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Radiation:
• Photobiomodulation in the sublingual region
In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
• Photobiomodulation in the spinal cord
Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
• Photobiomodulation in the radial artery
Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.

Locations

Country	Name	City	State
Brazil	UNINOVE	São Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
University of Nove de Julho

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oxidative stress	The concentration of endogenous nitrite will be evaluated in serum samples using the Total Nitric Oxide and Nitrate/Nitrite Parameter Assay Kit (R&D) according to the manufacturer´s instructions. Briefly, 50 µL sample will be incubated in 96 well plates with the reaction diluent provided by the kit, Griess Reagent I and II for 10 min at room temperature. Reactions will be read at 540 nm.	Through study completion, about one year.
Primary	Tumor Necrosis Factor Alpha	The quantification of the serum levels of IL-10 and TNFa will be performed using the Human IL-10 and THF-alpha ELISA MAX (Biolegend), according to the manufacturer's instructions. Briefly, plates will be coated with the capture anti-IL-10 or anti-TNF-alpha monoclonal antibody for 18h at 8°C, washed and then incubated with the reagent provided by the kit to block non-specific binding and to reduce background. Samples will be added to each well at room temperature for 2h and after wash, detection antibody solution will be added. Reactions will be revealed with the Avidin-HRP solution and the absorbance will be read at 450nm.	Through study completion, about one year.
Primary	Interleukin-10	The quantification of the serum levels of IL-10 and TNFa will be performed using the Human IL-10 and THF-alpha ELISA MAX (Biolegend), according to the manufacturer's instructions. Briefly, plates will be coated with the capture anti-IL-10 or anti-TNF-alpha monoclonal antibody for 18h at 8°C, washed and then incubated with the reagent provided by the kit to block non-specific binding and to reduce background. Samples will be added to each well at room temperature for 2h and after wash, detection antibody solution will be added. Reactions will be revealed with the Avidin-HRP solution and the absorbance will be read at 450nm.	Through study completion, about one year.
Secondary	EDSS	The participants will be evaluated before and after treatment using the Expanded Disability Status Scale administered by a physiotherapist.	Through study completion, about one year.